Opus Genetics announced positive safety and efficacy results from the low-dose cohort of its BIRD-1 clinical trial for OPGx-BEST1, showing clinically meaningful visual function improvements with no serious adverse events. This positive data significantly de-risks the drug candidate and provides a strong foundation for future development, including alignment with the FDA on potential pivotal endpoints.
Opus Genetics reported favorable safety and efficacy data from the low-dose cohort of its Phase 1/2 BIRD-1 trial for OPGx-BEST1, a gene therapy for inherited retinal diseases. All five participants showed clinically meaningful improvements in visual function, with structural improvements in four, and importantly, no serious adverse events. This positive outcome is a significant de-risking event for the company's lead asset, potentially accelerating its path to market. The FDA's alignment on microperimetry improvement as a potential pivotal endpoint is also a crucial long-term positive, providing clarity for future trial design. Short-term, this news should lead to a positive market reaction for IRD, while long-term, it enhances the company's prospects for addressing a significant unmet medical need and achieving multiple clinical inflection points.